Risk Factors Update Summary
- The company paused the development of the Kv7 program and explored strategic alternatives, receiving a Non-Binding Term Sheet for a potential acquisition from Tango.
- Future product candidates may cause undesirable side effects, potentially leading to delay or halt of clinical trials.
- Accumulated deficit increased from $120.9 million to $156.0 million as of December 31, 2023.
- Reduction in workforce by 10 employees in October 2023 may impact financial results.
- Operating losses increased from $35.1 million to $45.2 million for the years ended December 31, 2023 and 2022, respectively.
- Loss of institutional knowledge due to restructuring actions could negatively affect operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1768446&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.